Ultrahuman’s racing partnership is about more than lap times; the bigger story is the teenage years when female healthspan takes shape.
Alamar and Nightingale will hunt rare, low-level proteins in UK Biobank blood for signs of dementia and Parkinson’s long ...
A late-breaking slot in Boston will bring fresh data on an experimental drug that aims to turn down tau production in the ...
Six-month University of Surrey RCT sees better endothelial function, less arterial stiffness and lower systolic pressure – ...
L-Nutra Health launches a clinician-led metabolic program in London, built on a patented plant-based diet designed to mimic fasting. Valter Longo has spent more than 25 years studying fasting at the ...
A Phase 1 study of MNA-001, which targets TREM2, saw age-linked markers in elderly volunteers shift toward levels seen in ...
Emory researchers say a 10-protein plasma signature outperformed the established marker, though it remains a research finding.
Fractyl’s Revita hit its six-month goal in a sham-controlled pivotal trial, and the FDA filing is planned for late Q4 2026.
Latus Bio's Nature Communications paper models how lowering MSH3 could slow somatic instability – and buy years, perhaps decades.
Twelve abstracts head to The Liver Meeting, including a real-world comparison with resmetirom and four on investigational efruxifermin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results